Blueprint Medicines Corp

Blueprint Medicines — Q4 2024 Earnings Presentation

12 slides from Blueprint Medicines's earnings presentation, Feb 13, 2025

  1. Slide 1: Blueprint Medicines

    Blueprint Medicines Driving growth and innovation with operational excellence Fourth quarter and full-year 2024 financial results February 13, 2025

  2. Slide 2: Fourth quarter and full-year 2024 financial results

    Fourth quarter and full-year 2024 financial results AYVAKIT CLINICAL FINANCIAL INTRODUCTION PERFORMANCE PROGRESS RESULTS Kate Haviland Philina Lee, PhD Becker Hewes, MD Mike Landsittel Chief Executive Officer Chief Commercial Officer Chief Medical Officer Chief Financial Officer 2

  3. Slide 3: Forward-looking statements

    Forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding its plans, strategies, timelines and expectations for the company’s operations,

  4. Slide 4: 2025 guidance progresses AYVAKIT toward $2 billion by 2030

    2025 guidance progresses AYVAKIT toward $2 billion by 2030 $4,000 AYVAKIT REVENUE GROWTH ~45% $2,000 $, MILLIONS = Actual $680-710 = Expected $479 Implied ~24% CAGR (2025 midpoint to 2030 goal) $204 $111 $53 2021 2022 2023 2024 2025 2030 Franchise Peak 2025 guidance represents robust YoY growth cons

  5. Slide 5: Our capital allocation strategy aligns with core growth drivers

    Our capital allocation strategy aligns with core growth drivers HIGH GROWTH DURABLE FINANCIAL PROFILE Drive continued AYVAKIT Advance R&D innovation revenue growth to fuel long-term growth Extend long-term SM franchise with elenestinib development CONTINUOUS INNOVATION Accelerate and expand developm

  6. Slide 6: AYVAKIT achieved 135% year-over-year growth in 2024

    AYVAKIT achieved 135% year-over-year growth in 2024 Q4 2024 HIGHLIGHTS AYVAKIT 135% REVENUE $479 PATIENTS GROWTH • Continued growth in patients on therapy $, MILLIONS • Trend toward multi-year durations of therapy in ISM • ~95% strongly agree they are satisfied with AYVAKIT1 PAYERS $204 • Continued

  7. Slide 7: Driving breadth and depth with significant headroom for continued growth

    Driving breadth and depth with significant headroom for continued growth PRESCRIBING BREADTH PRESCRIBING DEPTH Cumulative prescribers with Cumulative prescribers with 1+ patients SM on therapy 2+ SM patients on therapy since ISM approval since ISM approval 2 patients 1 patient 3-4 patients 2+ patien

  8. Slide 8: Building on our success to drive growth in 2025 and beyond

    Building on our success to drive growth in 2025 and beyond Activate more patients and providers with new initiatives, including peer-to-peer and direct-to-consumer programs 2025 AYVAKIT Generate AYVAKIT and real-world data catalyzing urgency to treat investment priorities Launch ISM in additional ge

  9. Slide 9: Updated AYVAKIT data support strong safety and efficacy profile

    Updated AYVAKIT data support strong safety and efficacy profile plus positive impact on bone health AYVAKIT 3-YEAR FOLLOW-UP CLINICALLY MEANINGFUL DATA FROM PIONEER TRIAL 1 IMPROVEMENT IN BONE DENSITY 3 Lumbar Spine Femoral Neck Total Femur • In commercial setting, >90% of patients who 5 initiated t

  10. Slide 10: Multiple clinical data milestones anticipated in 2025 and beyond

    Multiple clinical data milestones anticipated in 2025 and beyond BLU-808 PROOF-OF-CONCEPT STRATEGY UNIVERSE OF ALLERGIC & INFLAMMATORY DISEASES Move rapidly into areas where targeting KIT has been de-risked Respiratory Skin • Allergic asthma • Chronic urticaria • Chronic spontaneous urticaria • Alle

  11. Slide 11: Strong and durable financial profile entering 2025

    Strong and durable financial profile entering 2025 Three Months Three Months FY Ended FY Ended Statement of Operations (unaudited) Ended Ended 12/31/2024 12/31/2023 12/31/2024 12/31/2023 Total revenue $146.4M $72.0M $508.8M $249.4M Net product sales $144.1M $71.0M $479.0M $204.2M Collaboration, lice

  12. Slide 12: Blueprint Medicines

    Blueprint Medicines Driving growth and innovation with operational excellence

Blueprint Medicines — Q4 2024 Earnings Presentation on 6ix